Medicine and health industry is the key direction for the development of strategic emerging industries in China, and it is an important engine for boosting Beijing's innovation and development. In order to accelerate the development of new quality productivity, to promote higher quality and higher level of development of the pharmaceutical and health industry, specially formulated this action plan.

First, the development goals

By 2026, the total size of the pharmaceutical and health industry reached 1.25 trillion yuan (of which, the pharmaceutical industry revenue reached 240 billion yuan), fixed asset investment of more than 10 billion yuan per year. To realize the world's leading scientific discoveries and technological breakthroughs 5-8, new approval of 10 listed innovative drugs, innovative medical devices 30; "three doctors" linkage development level further enhancement, the new 1-2 research hospitals; the introduction of cultivation of multi-level professionals more than 10,000 people; the city's pharmaceutical and health industry investment fund prying the community 20 billion yuan a year; high-quality characteristics of the industry and risk investment. The city's pharmaceutical and health industry investment fund will mobilize social venture capital of 20 billion yuan per year, and there will be 10 high-quality specialty parks. The carrying capacity of the industry is further enhanced, and the formation of a modern pharmaceutical and health industry cluster with global influence is accelerated.

Second, the key tasks

(a) to strengthen the source of innovation, accelerate the transformation of cutting-edge technology results

1. Strengthen the national strategic scientific and technological power to lead the role. We will provide full services for the construction of national laboratories, and strengthen research breakthroughs on major scientific issues and key technologies in the field of degenerative diseases. Enhance the leading role of national key laboratories in innovation and industrial support. Promote the construction and operation of large scientific devices in the field of life sciences and open them to the world. Support leading science and technology enterprises to form innovation consortiums with national research institutions and universities to collaborate on basic and frontier scientific research, key core technology research, and system integration and innovation.

2. Develop and expand new innovation forces. Stable support for new research and development institutions in the field of life sciences, actively undertake major national strategic scientific and technological tasks, carry out high-level original research, carry out common technology research for industrial needs, improve the mechanism for the transformation of scientific and technological achievements, and promote the incubation and breeding of enterprises. In the fields of medical translational research, respiratory infectious diseases, gene storage applications, ribonucleic acid and other areas, set up a number of innovative institutional mechanisms of research institutions. Support foreign-funded R&D centers to develop and integrate into Beijing's innovation system.

3. Accelerate the output of major achievements in the field of life sciences. We have deployed "nuclear explosion point" special projects in the field of cellular gene therapy, brain-computer interface, synthetic biology and other cutting-edge technologies, which will lead to disruptive and leading scientific discoveries and technological breakthroughs. To support the analysis of brain cognitive principles, aging mechanisms and other forward-looking major scientific issues of basic research; layout-oriented reproductive health diseases, difficult and rare diseases and other applied basic research; strengthen the gene editing and other key core technology research industry urgently needed.

4. Promote clinical needs and market-oriented innovation and transformation. Supporting medical institutions to cooperate with national laboratories, new research and development institutions, universities and institutes, and enterprises, integrating the advantages of basic and clinical research, creating 5-10 research bases combining basic and clinical research, and accelerating the speed of basic research to clinical transformation. Implement the "dual-responsible" model of clinicians and scientists to carry out collaborative research. Adopting the mode of "industry asks the questions, reveals the list of commanders" to promote the cooperation between enterprises and scientists. Support the construction of technological innovation centers in the direction of animal models of diseases and synthetic biological manufacturing. Guide the new hospital to strengthen the application of new technologies and products, and support the functional layout of the transformation of scientific and technological achievements planned in advance.

(B) Strengthen clinical research, and enhance the synergy between medical research and production

5. Improve the quality of clinical research. Promote the conditional hospitals to set up full-time and part-time clinical research team, improve the assessment mechanism, and strengthen the incentives for the transformation of scientific and technological achievements. The construction of clinical research consortiums, national medical centers, research ward demonstration units as the core to carry out high-level clinical research and medical research transformation. Enhance the ability of clinical researchers to participate in or undertake international multi-center clinical research.

6. Play the role of clinical support for the industry. Optimize the process of clinical trial project initiation by clinical institutions, and compress the time of clinical trial initiation to less than 25 weeks. The city is also promoting the expansion of mutual recognition of medical ethical review results and the establishment of a monitoring system to enhance the effectiveness of mutual recognition. Implementing the monitoring of the whole process of clinical trials and linking the monitoring results to the post-subsidy policies of clinical organizations. Establishment of the city's clinical trial information platform to realize the "one network".

7. Promote the high-level development of research hospitals. The research hospitals have been included in the medical insurance program. Support research hospitals to cooperate with the city's tertiary hospitals to carry out early clinical research on cell therapy. Supporting research hospitals to participate in the construction of clinical research consortia. Attract global high-level clinical trials and domestic first landmark projects, and support innovative varieties to carry out globally synchronized international multi-center clinical trials. Promote the construction of research hospitals of Capital Medical University.

(C) Stimulating the value of data elements and promoting digital empowerment

8. Implementing medical big data sharing and application. The construction of the city's shared outpatient emergency, hospitalization, medical examination, research and other electronic medical record system. Promote the sharing of standardized and informatized clinical research data, clarify data desensitization standards, and open up data links between hospitals. Promote the interconnection and mutual recognition of test results and medical images in the city's tertiary hospitals. Promote hospitals to carry out the registration, evaluation and circulation of medical big data, and expand the application of innovative research and development.

9. Promote the digital management and use of clinical samples. The establishment of the city's open, fully privacy-protected clinical sample sharing information system and resource quality evaluation system, to promote some of the industry's urgent need for standardized collection and storage of samples for digital conversion, to improve the overall efficiency of the use of clinical sample resources. Improve the application of clinical samples in the research of new technologies and methods of diagnosis and treatment, and the development of new drugs.

10. Promote the safe cross-border flow of medical data. To build a communication mechanism for the approval of cross-border flow of data, strengthen the services of data exit security assessment, personal information exit standard contract filing, etc., to ensure data exit compliance. Relying on the city's Collaborative Innovation Center for Data Cross-border Security and Industrial Development and the Data Security and Governance Public Service Platform, the city has strengthened its risk assessment and compliance guidance for data exit from pharmacovigilance and other business management scenarios.

11. Accelerate the development of the industry empowered by artificial intelligence technology represented by medical big models. Support the development and application of medical big models, promote the research and application of digital therapies, AI-assisted treatment and other products, and promote AI technology-enabled new drug research and development. Accelerate the construction of data bases for medical care, medical insurance and drug supervision, carry out data cleaning and governance in a refined manner, and promote data circulation. Guiding arithmetic enterprises to increase support for AI medical, exploring the configuration of the construction of a trusted computing environment.

(D) Create a full-process service system to accelerate the process of research and development to application

12. Establish a service mechanism to link the research and development of medicines and devices. To establish a full-process service mechanism to accelerate the R&D and application of innovative medicines and devices, to strengthen the tracking service in key aspects such as clinical trials, registration and listing, production and landing, and application in hospitals, to solve problems in a timely manner, to strengthen the assessment of work, and to enhance the level of service.

13. Improve review efficiency. Actively docking the national drug supervision and management of relevant units, do a good job of communication and coordination. The company's main goal is to provide the best possible service to its customers, and to provide the best possible service to its customers in the future. The role of the Beijing Service Station of the National Medical Device Technical Review Organization and the Beijing Drug and Medical Device Innovation Service Station has been utilized to broaden the channels of review and exchange, and to strengthen the guidance services. It is also necessary to shorten the time of drug import inspection and improve the efficiency of customs clearance.

14. Accelerate the application of innovative medicines and devices in hospitals. To promote the medical institutions to establish a regular convening of drug management and drug therapeutics committee working meeting of the long-term mechanism. The company's business is to provide a wide range of products and services to the public, and to provide a wide range of products and services to the public. Guiding municipal hospitals to speed up the application of innovative medicines into hospitals, and to admit medicines into hospitals as soon as possible in accordance with the principle of "should be dispensed as much as possible" for medicines included in the medical insurance catalog. Qualified innovative medical devices involving new medical technologies can be declared as new medical service price items at any time, and if the conditions are met during the trial period, medical institutions can apply for unified pricing and medical insurance demonstration. Through ordering, first purchase and other ways to promote medical device research and development, accelerate the application of innovative products into the hospital.

15. Optimize the medical insurance payment settlement mode. Further promote the national health insurance negotiated drugs "dual-channel" work (designated medical institutions and designated retail pharmacies), continue to expand the scope of the pilot, explore the non-national health insurance negotiated drugs into the pilot scope. Incorporating eligible innovative medicines and devices and related technical services into the city's Disease Diagnosis-Related Grouping (CHS-DRG) payment exclusion payment scope. Select 1-2 hospitals to carry out the pilot of AI medical devices, and explore the construction of the admission procurement and settlement model.

16. Enrich the multi-level commercial medical insurance system. In accordance with the principles of safety, efficacy, and economy, we will promote the inclusion of innovative medicines that are not included in the national health insurance drug catalog into the "Beijing Universal Health Insurance". Commercial insurance companies are encouraged to develop insurance products for innovative and urgently needed innovative drugs such as cellular gene therapy, which complement basic medical insurance.

(V) Optimize the structure of varieties, and promote industrial capacity leap

17. Promote the innovative development of drugs. Promote the next generation of double polyantibodies, infectious disease vaccines and other large varieties of R & D market application, support the international registration and export of drugs, promote the quality of generic drugs to improve the output of one billion yuan of large varieties of 30. Support the rapid formation of industrial increment for varieties with high market potential such as cell therapy and gene drugs. In the field of inflammation, infection and other areas, to promote the research and development of new targets, new mechanisms of heavyweight drugs.

18. Promote the quality and efficiency of medical devices. We will grow the scale of medical robotics and other industries, promote international high-end medical device production lines, promote the production of imported products in Beijing, and increase the proportion of medical device output value in the pharmaceutical industry. Carry out key core technology research in life support and other fields. Support enterprises to accelerate product registration overseas, expand sales channels, and enhance market development capabilities.

19. Promote the development of Chinese medicine and innovation. Promote the development of innovative Chinese medicine, improved new Chinese medicine, ancient classic Chinese medicine compound preparation, and promote the development and application of digital Chinese medicine diagnostic and treatment equipment. Promote the clinical application of large varieties of famous and excellent Chinese patent medicines in line with modern medical norms, and promote the use of in-hospital preparations for transfer within the medical association and transformation into new drugs. Build Chinese medicine international comprehensive service platform and online trading platform, to develop the international market.

20. Deepen the synergistic development of Beijing-Tianjin-Hebei pharmaceutical industry. Promote the construction of Beijing-Tianjin-Hebei life and health clusters, strengthen planning, policy and elemental synergies, build industrial corridors, enhance upstream and downstream synergies and cooperation, and carry out joint investment relying on industry chain mapping. Promote mutual recognition of medical ethics review results in the Beijing-Tianjin-Hebei region. Explore the establishment of a long-term cooperation mechanism for cross-regional synergy and standardization of drug and equipment regulation. Promote the synergy of listed procurement in the three regions. Promote the Beijing-Tianjin-Hebei region health emergency material reserve system synergistic construction.

(F) Classification and precise measures to help the echelon development of enterprises

21. Vigorously gather leading enterprises. Attract 3-5 multinational enterprises to develop in Beijing. Support multinational enterprises in Beijing to upgrade their industrial capacity, expand the scale of their R&D centers, and introduce leading technologies and varieties. Utilizing the influence of top scientists and renowned doctors, and playing the role of research wards and other platforms, no less than five leading enterprises will be attracted to land and develop.

22. Enlarge and strengthen high-growth backbone enterprises. Support enterprises to expand their R&D pipeline, enhance their ability to take on the innovations of national laboratories, new R&D institutions and universities and institutes, and promote their integration and development with start-ups. Support enterprises to set up overseas R&D centers, innovation funds, and carry out global investment and M&A. Support the accelerated development of enterprises with a revenue scale of 1-2 billion yuan, and strive to have 15 enterprises realize a revenue scale of more than 5 billion yuan within three years.

23. Continuously cultivate cutting-edge technology enterprises founded by scientists. The training of a number of preferred partner-type CEOs to serve scientists in entrepreneurship, to promote the transformation of scientists' cutting-edge technology achievements, incubation of more than 20 new scientists to lead the creation of cutting-edge technology enterprises. Play the role of enterprise "service package" mechanism, provide "nanny" services, and promote it to become a unicorn, specializing in new "small giant" enterprises.

24. Enhance the scale and efficiency of third-party service platforms. No less than five domestic and foreign high-quality pharmaceutical outsourcing service platforms have been introduced, and the layout of international registration, sales and other key link service platforms, and the cultivation of carrier delivery, disease model animals and other specialty technology platforms. The company will also improve the one-stop service capability of the leading third-party R&D and production service providers of biopharmaceuticals, cellular gene therapy, and small molecule drugs, and accelerate the expansion of its global business.

25. Promote the upgrading of incubator capacity and high-level operation. No less than three internationally renowned professional incubators and gas pedals will be introduced. The incubators will be centrally located in regions rich in innovation resources, and the gas pedals will be centrally located in regions with well-developed industrial elements, providing incubation projects with validation platforms, investment funds, and other guaranteed services. Promote the incubator to form a service model covering the whole chain of "discovery-validation-maturation-incubation".

26. Injecting capital into the water. The city's pharmaceutical and health industry investment fund plays a supporting role in the development of the industry, strengthens the driving effect on the investment of social capital, and focuses on supporting the early transformation and industrialization. Gather global venture capital funds and promote cooperation between state-owned investment platforms and venture capital funds. Establish a service channel for enterprises to go public and create a favorable environment for landing on the Beijing Stock Exchange. Support enterprises to land on the domestic and international capital markets, and create 20 new listed enterprises.

(VII) Implementing all-round introduction and cultivation to create a highland for international talents

27. Provide services for the introduction of global top talents. Attracting strategic scientists to set up research teams and laboratories in Beijing; strengthening the introduction of top talents in the fields of brain-computer interfaces, synthetic biomanufacturing, etc.; and intensifying the introduction of high-end talents in cross-disciplines in the fields of medicine and artificial intelligence. Relying on new R&D organizations, universities and institutes, we will strengthen the allocation of scientific research resources and give more autonomy in terms of financial guarantee.

28. Strengthen the introduction of multi-level professionals. We will do a good job of providing special services for pharmaceutical and healthcare talents, attracting CEOs, chief medical officers and other management talents with international backgrounds, experienced industrial talents in international registration of drugs and medicines and clinical trial statistics, as well as key core technological talents in the direction of gene editing and other aspects of development in Beijing, and providing them with good services and guarantees for their work and life.

29. Carry out diversified talent cultivation. Relying on the innovative talent cultivation model of joint medical education and research, explore the implementation of the training program for clinical scientists. Support the hospital to send outstanding talents to study in domestic and foreign clinical research institutions, to create a team of talents in the transformation of scientific and technological achievements. Through the implementation of the service scientists entrepreneurial CEO talent training courses, medicine advanced seminars, health care field innovation training program, etc., to enhance the ability level of complex management personnel.

(VIII) Highlighting regional advantages and building a pattern of industrial agglomeration and linked development

30. Strengthening spatial supply and regional coordination. Planning to add no less than 3,000 acres of industrial land available for industrial use, to promote the completion of 1.2 million square meters of standard factory buildings, new standard factory buildings 1.8 million square meters. Promote the construction of international cooperation industrial parks and enhance the international operation level of the parks. Strengthen the Haidian District, Daxing District, Changping District, Beijing Economic and Technological Development Zone and other industry-led districts, and support the city's sub-center and other areas with advantages to strengthen the industrial layout, to build a "four-core multi-point" industrial pattern.

31. Promote the Haidian District to create a new benchmark of intellectual and medical integration. Accelerate the construction of the Zhongguancun Science City International Medical Valley and Zhongguancun Comprehensive Bonded Zone, and build specialty parks in Shangzhuang and Xisanqi. Construct a number of high-level platforms such as proof-of-concept centers and technology transfer centers to create a core carrying area for original innovation incubation. Promote cutting-edge technology innovations such as brain-computer interfaces, promote the development of innovative drugs and high-end medical devices in niche areas, advance the application of medical grand models, accelerate the cultivation of new digital medical forms, and form the advantages of the smart medical integration industry.

32. Promote Changping District to build a new engine of innovation speed. Relying on national laboratories and new research and development institutions, it has led to the breakthrough of "0 to 1". Focusing on cellular gene therapy, synthetic biology manufacturing and other fields, building and utilizing research hospitals and other platforms, accelerating the construction of the third phase of the Zhongguancun Life Science Park, promoting the construction of industrial parks such as the International Medical Device City, and building a world-leading life science innovation corridor. Give full play to the advantages of "Life Valley" and "Energy Valley" of Future Science City, and build an innovation demonstration zone for the bio-manufacturing industry. It will also create a globally competitive pharmaceutical and healthcare industry development center.

33. Promote the construction of advanced manufacturing in Daxing District. Accelerate the north-south expansion of Daxing biomedical industry base, layout of nucleic acid drugs, high-end medical devices and other characteristics of the park. The construction of the Capital Medical University campus is being pushed forward, and a new mechanism is being used to plan and build the university science and technology park. Promote the landing of the National Medical Center. Strengthen the synergy between the pharmaceutical base and related industrial parks to realize the centralized landing of high-end manufacturing links.

34. Promote the construction of a new landmark for pharmaceutical manufacturing in the Beijing Economic-Technological Development Area. It is the first time in the world that a company is required to provide a full range of services to its customers. Yizhuang" brand name. Actively implement the industrial space expansion and urban renewal program, step by step to promote the development of industrial land space, to create a new drug manufacturing heights.

Third, the guarantee mechanism

play the role of the Beijing Municipal Pharmaceutical and Health Coordination Joint Committee, strengthen the coordination, to project, task-oriented way to promote the implementation of the tasks in detail. The company's financial resources will be strengthened. The Zhongguancun pilot reform and the "two zones" construction system advantages, to promote a number of pilot policies to achieve results. Relying on national platforms such as the China International Fair for Trade in Services and the Zhongguancun Forum, organize high-level internationalized parallel forums in the field of medicine and health. Create internationalized professional conference brands to enhance Beijing's international influence in the fields of biomedicine and life sciences. Attracting scientific publishing and information analysis companies with top international academic journals to come to Beijing, playing the role of gathering international elements, and accelerating the construction of a high-level open ecology.